ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "C-reactive protein (CRP)"

  • Abstract Number: 0728 • ACR Convergence 2021

    Intra-articular Canakinumab (anti-interleukin-1β) for Treatment of Symptomatic Knee Osteoarthritis: A Randomized, Double-blind, Placebo and Naproxen-controlled Phase II Study

    Philip Conaghan1, Xavier Chevalier2, Linda Mindeholm3, Ursula Schramm3, Jens Praestgaard3, Abdelkader Seroutou3, Ronenn Roubenoff3 and Matthias Schieker3, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2Henri Mondor University Hospital and Paris University XII, UPEC, Créteil, France, Créteil, France, 3Novartis Institutes for Biomedical Research, Basel, Switzerland, Basel, Switzerland

    Background/Purpose: Knee osteoarthritis (OA) is a common musculoskeletal disease associated with pain and functional impairment. There are few effective therapies, often limited by side-effects.1 This…
  • Abstract Number: 0796 • ACR Convergence 2021

    Validation of the Simplified Disease Activity Index (SDAI) with a Quick Quantitative C-reactive Protein Assay (SDAI-Q) in Patients with Rheumatoid Arthritis: A National, Multicenter Study

    Julia Schally1, Henning Christian Brandt2, Jan Brandt-Jrgens3, Gerd Burmester4, Hildrun Haibel5, Henriette Käding1, Kirsten Karberg6, Susanne Lüders7, Burkhard Muche1, Mikhail Protopopov4, Valeria Rios Rodriguez4, Murat Torgutalp4, Maryna Verba8, Silke Zinke9, Denis Poddubnyy10 and Fabian Proft4, 1Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, 2Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, 3Rheumatologische Schwerpunktpraxis, Berlin, Germany, 4Charité University Medicine Berlin, Berlin, Germany, 5Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 6Praxis für Rheumatologie und Innere Medizin,, Berlin, Germany, 7Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Berlin, Germany, 8Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, 9Rheumapraxis Berlin, Berlin, Germany, 10Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany

    Background/Purpose: Therapeutic decisions in RA patients should be based on regular disease activity assessment using scores like the Simplified Disease Activity Index (SDAI) or the…
  • Abstract Number: 0833 • ACR Convergence 2021

    Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in German Real-World Practice: Interim Results from a Post-Marketing Observational Study

    Torsten Witte1, Uta Kiltz2, Florian Haas3, Elke Riechers4, Ulrich Prothmann5, Daniela Adolf6, Carsten Holland7, Rouven Hecht8, Alexander Rössler7, Kirsten Famulla8, Konrad Götz8 and Klaus Krüger9, 1Hannover Medical School, Hannover, Germany, 2Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, 3Internistisch-Rheumatologische Facharztpraxis, Tübingen, Germany, 4Department for Rheumatology and Immunology, Hannover Medical University, Hannover, 5Knappschaftsklinikum Saar, Püttlingen, Germany, 6StatConsult GmbH, Biometry and Data Management, Magdeburg, Germany, 7AbbVie Deutschland GmbH & Co. KG, Wiesbaden, 8AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, 9Rheumatological Practice Center, Munich, Germany

    Background/Purpose: Upadacitinib (UPA) is a Janus kinase inhibitor that has been shown to be effective and well tolerated in patients with rheumatoid arthritis (RA) in…
  • Abstract Number: 0914 • ACR Convergence 2021

    Response to Certolizumab Pegol in Patients with Non-Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Cut-Offs: Post-Hoc Analysis from a Phase 3 Multicenter Study

    Philip Robinson1, Stephen Hall2, Bengt Hoepken3, Lars Bauer3, Eleni Demas4, Mindy Kim5 and Atul Deodhar6, 1University of Queensland School of Clinical Medicine, Brisbane, Queensland, Australia, Herston, Australia, 2Emeritus Research and Monash University, Melbourne, Australia, Melbourne, Australia, 3UCB Pharma, Monheim am Rhein, Germany, 4UCB Pharma, Slough, United Kingdom, 5UCB Pharma, Smyrna, GA, 6Oregon Health & Science University, Portland, OR

    Background/Purpose: Certolizumab pegol (CZP), an Fc-free, PEGylated tumor necrosis factor (TNF) inhibitor, has previously demonstrated efficacy and safety in patients with radiographic (r) and non-radiographic…
  • Abstract Number: 1196 • ACR Convergence 2021

    Morning Stiffness Already Associates with Systemic Inflammation and Subclinical Joint Inflammation in the Pre-RA Phase of Arthralgia

    Doortje Krijbolder1, Fenne Wouters1, Elise van Mulligen2 and Annette H.M van der Helm-van Mil1, 1Leiden University Medical Center, Leiden, Netherlands, 2Erasmus Medical Center, Rotterdam, Netherlands

    Background/Purpose: Morning stiffness (MS) is characteristic for Rheumatoid Arthritis (RA) and associates with markers of systemic and local inflammation in RA-patients. In patients with arthralgia,…
  • Abstract Number: 1208 • ACR Convergence 2021

    Composite Articular Index Including Acute Phase Reactants Should Not Be Used in Patients with Rheumatoid Arthritis Treated with Il6 Inhibitors but May Be Useful in Those Receiving Jak Inhibitors: Ultrasound Evidence

    Andrés Ponce1, Beatriz Frade-Sosa2, Ramirez Julio3, Núria Sapena1, Roberto Gumucio2, Virginia Ruiz-Esquide2, Rosa Morlà2, Marta Bassas2, Juan D Cañete4 and Jose A Gomez-Puerta2, 1Rheumatology Department, Hospital Clínic, Barcelona, Spain, 2Hospital Clínic de Barcelona, Barcelona, Spain, 3Hospital Universitari Clinic, Barcelona, Spain, 4Rheumatology Department, Hospital Clinic, Barcelona, Spain

    Background/Purpose: IL6 inhibitors (IL6i) have a dramatic effect on the reduction of C reactive protein (CRP) that does not always correlate with a significant improvement…
  • Abstract Number: 1401 • ACR Convergence 2021

    Utility of CRP and ESR in the Assessment of Giant Cell Arteritis Relapse in a Phase 2 Trial of Mavrilimumab

    Sebastian Unizony1, Maria C. Cid2, Daniel Blockmans3, Elisabeth Brouwer4, Lorenzo Dagna5, Bhaskar Dasgupta6, Bernhard Hellmich7, Eamonn Molloy8, Carlo Salvarani9, Bruce Trapnell10, Kenneth Warrington11, Ian Wicks12, Manoj Samant13, Teresa Zhou13, Lara Pupim13 and John F Paolini13, 1Vasculitis and Glomerulonephritis Center, Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, 2Vasculitis Research Group. Department of Autoimmune Diseases. Hospital Clínic. University of Barcelona, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain, 3General Internal Medicine, UZ Leuven, Leuven, Belgium, 4University Medical Center Groningen, Groningen, Netherlands, 5Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute; Vita-Salute San Raffaele University, Milan, Lombardia, Italy, 6Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, 7Department of Internal Medicine, Rheumatology, and Immunology, Medius Kliniken, Kirchheim unter Teck, Germany, 8St Vincent's University Hospital, Dublin, Ireland, 9Unità Operativa di Reumatologia, Azienda USL-IRCCS di Reggio Emilia, Italy, Reggio Emilia, Italy, 10Translational Pulmonary Science Center, Cincinnati Children’s Hospital, Cincinnati, 11Mayo Clinic, Rochester, Minnesota, 12Walter & Eliza Hall Institute & Melbourne Health, Melbourne, Australia, 13Kiniksa Pharmaceuticals Corp., Lexington, MA

    Background/Purpose: Although giant cell arteritis (GCA) relapse is mostly defined by the recurrence of GCA signs/symptoms, in patients treated only with glucocorticoids, the C-reactive protein…
  • Abstract Number: 1795 • ACR Convergence 2021

    Validation of the Disease Activity Index for Psoriatic Arthritis (DAPSA) with a Quick QuantitativeC-reactive Protein Assay (Q-DAPSA) in Patients with Psoriatic Arthritis (PsA): A Prospective,national, Multicenter Study

    Fabian Proft1, Julia Schally2, Henning Christian Brandt3, Jan Brandt-Jrgens4, Gerd Burmester1, Hildrun Haibel5, Henriette Käding2, Kirsten Karberg6, Susanne Lüders7, Burkhard Muche2, Mikhail Protopopov1, Judith Rademacher1, Valeria Rios Rodriguez1, Murat Torgutalp1, Maryna Verba8 and Silke Zinke9, 1Charité University Medicine Berlin, Berlin, Germany, 2Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, 3Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, 4Rheumatologische Schwerpunktpraxis, Berlin, Germany, 5Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 6Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, Berlin, Germany, 7Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Berlin, Germany, 8Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, 9Rheumapraxis Berlin, Berlin, Germany

    Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease with multiple musculoskeletal and dermatological manifestations. Due to this multifaceted clinical appearance, international guidelines do not provide…
  • Abstract Number: 1807 • ACR Convergence 2021

    Relationships Between Fatigue and Hemoglobin/C-Reactive Protein Levels and Associations Between Fatigue and Clinical Response in Patients with Active Psoriatic Arthritis: Results from Two Randomized Controlled Trials of Guselkumab (TREMFYA®)

    Proton Rahman1, Philip Mease2, Atul Deodhar3, Laure Gossec4, Arthur Kavanaugh5, Soumya Chakravarty6, Alexa Kollmeier7, Yan Liu8, Xiwu Lin8, May Shawi9 and Chenglong Han8, 1Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, 2Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 3Oregon Health & Science University, Portland, OR, 4Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, 5University of California San Diego, La Jolla, CA, 6Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, 7Janssen Research & Development, LLC, La Jolla, CA, 8Janssen Research & Development, LLC, Spring House, PA, 9Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada

    Background/Purpose: Fatigue is a key patient (pt)-reported symptom of psoriatic arthritis (PsA).1,2 Utilizing data from the Phase 3 DISCOVER-1 (D1) and -2 (D2) studies, these…
  • Abstract Number: 1920 • ACR Convergence 2021

    Association of C-reactive Protein and Non-Steroidal Anti-inflammatory Drugs with Cardiovascular Events in Patients with Psoriatic Arthritis: A Time-dependent Cox Regression Analysis

    Ho Man Lam1, Ho So2, Isaac Cheng1, Edmund Li1, Priscilla Wong3, Tena Li1, Alex Lee1 and Lai-Shan Tam4, 1The Chinese University of Hong Kong, Hong Kong, Hong Kong, 2CUHK, Hong Kong, China, 3Prince of Wales Hospital, Hong Kong, Hong Kong, 4Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China (People's Republic)

    Background/Purpose: Psoriatic arthritis (PsA) is associated with accelerated atherosclerosis due to underlying inflammation. Whether inflammatory burden and drugs used to suppress inflammation over time are…
  • Abstract Number: 1891 • ACR Convergence 2020

    Impact of Utilising Smart Phone Application in Ankylosing Spondylitis: SMART- as Study

    Ashit Syngle1, Nidhi Garg2 and Kanchan Chauhan1, 1Healing Touch City Clinic, Chandigarh, Chandigarh, India, 2Chitkara University, Rajpura, Punjab, India

    Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the axial skeleton and characterized by inflammatory back pain, leading to decreased mobility,…
  • Abstract Number: 1904 • ACR Convergence 2020

    Clinical Features of Patients with Active Ankylosing Spondylitis Who Did Not Respond to Adalimumab but Responded to Ixekizumab: A Post-hoc Analysis

    Xenofon Baraliakos1, Rebecca Bolce2, David Sandoval2, Soyi Liu-Leage3, Vladimir Geneus3, David Adams3, Atul Deodhar4, Jessica Walsh5 and Joachim Sieper6, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, 2Eli Lilly and Company, Indianapolis, 3Eli Lilly and Company, Indianapolis, IN, 4Oregon Health & Science University, Portland, OR, 5University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, 6Charité Universitätsmedizin Berlin, Berlin, Germany

    Background/Purpose: Biologic therapy is recommended in patients with active ankylosing spondylitis (AS) despite adequate trial of NSAIDs. Biologic treatment in AS are currently limited to…
  • Abstract Number: 2006 • ACR Convergence 2020

    Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data

    Markus Rehberg1, Clemens Giegerich1, Amy Praestgaard2, Hubert van Hoogstraten3, Melitza Iglesias-Rodriguez2, Jeffrey R Curtis4, Jacques-Eric Gottenberg5, Andreas Schwarting6, Santos Castañeda7, Andrea Rubbert Roth8 and Ernest Choy9, 1Sanofi, Frankfurt, Germany, 2Sanofi, Cambridge, MA, 3Sanofi, Bridgewater, NJ, 4Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 5Strasbourg University Hospital, Strasbourg, France, 6Johannes Gutenberg University, Mainz, Germany, 7Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, 8Klinik für Rheumatologie, Kantonsspital St Gallen, St Gallen, Sankt Gallen, Switzerland, 9CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom

    Background/Purpose: Despite the existence of guidelines for DMARD treatment of RA, a more individualized approach to treatment is needed to maximize efficacy while minimizing risk…
  • Abstract Number: 0034 • ACR Convergence 2020

    Gene Expression Signatures in C-Reactive Protein High and Low Rheumatoid Arthritis

    Adam Cornish1, Kristin Wipfler1 and Kaleb Michaud2, 1FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 2University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Transcriptome profiling has expanded our ability to identify biomarkers and therapeutic targets and better understand disease progression in a wide variety of conditions. Serum…
  • Abstract Number: 0097 • ACR Convergence 2020

    Does Testing for SAA Is More Beneficial Than CRP for the Follow-up of Patients with FMF?

    Mert Oztas1, Serdal Ugurlu1, Oguzhan Selvi2, Bilgesu Ergezen1 and Huri Ozdogan1, 1Istanbul University-Cerrahpasa, Istanbul, Turkey, 2Okmeydani Research and Training Hospital, Istanbul, Turkey

    Background/Purpose: In order to follow subclinical inflammation and adjust the therapy for an optimal disease control, clinicians seek for readily accessible, affordable and reproducible markers.…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology